-
AMT-130 at Four Years: Hopeful Signs, Complex Controls
12 min read
Latest News
-
September 2026: This month in Huntington’s disease research
5 min read
September brought progress across the HD research landscape. From brain waves and visual thinking to DNA repeats, nutrition, inclusive care, new technologies, and encouraging SKY-0515 data, we round up a busy month in Huntington’s disease research.
-
Success! ASO drug reduces levels of mutant protein in Huntington's disease patients
11 min read
Amazing news from Ionis and Roche! HTTRx drug successfully lowers harmful huntingtin protein in spinal fluid
-
Switch off the genome editor when you’re done
7 min read
CRISPR genome editing just got an off-switch. We cut through the hype to explore the technology in HD
-
A new way of thinking about trials to prevent Huntington's disease
6 min read
Can we test drugs to delay or prevent the onset of Huntington's disease? New research suggests it's possible
-
New roles for huntingtin: removing a healthy protein to understand its function
7 min read
Completely removing normal huntingtin in adults may disrupt healthy brain function, a recent study suggests.
-
Precision huntingtin-lowering drug trials target the mutant protein
10 min read
WAVE Life Sciences launches PRECISION clinical trial to suppress the mutant Huntington's disease protein
-
A step forward for gene editing: CRISPR-Cas9 and HD
9 min read
Evolving CRISPR-Cas9 techniques can now be used to edit the HD gene in a living mouse brain.
-
Update confirms Huntington's disease 'gene silencing' trial on track
10 min read
Ionis says its trial of HTTRx, intended to lower huntingtin protein, is fully recruited and plans to extend it
-
New study reveals a potential HD biomarker
8 min read
A potential HD biomarker has been uncovered in a recent clinical study
-
Has a "wonder drug" for dementia been discovered? (Spoiler alert: no.)
8 min read
Media reports of a wonder drug for neurodegenerative diseases like Huntington's disease are overhyped
-
Huntington's Disease Therapeutics Conference 2017 – Day 3
5 min read
HDBuzz summarises final day of the 2017 Huntington's Disease Therapeutics Conference in Malta
HDBuzz Trial Tracker
Show 8 more Show less
Updates from the ongoing Phase 3 INVEST-HD trial of votoplam
Updates from the Phase 1b/2a REGEN4HD trial of neural stem cell therapy hNSC-01
Updates from the ongoing Phase 2/3 FALCON-HD trial of SKY-0515
